Non-Anticoagulant Low Molecular Weight Heparins for Pharmaceutical Applications

Yilan Ouyang; Yanlei Yu; Fuming Zhang; Jianle Chen; Xiaorui Han; Ke Xia; Yiming Yao; Zhenqing Zhang; Robert J. Linhardt

doi:10.1021/acs.jmedchem.8b01551

Non-Anticoagulant Low Molecular Weight Heparins for Pharmaceutical Applications

Yilan Ouyang, Yanlei Yu, Fuming Zhang, Jianle Chen, Xiaorui Han, Ke Xia, Yiming Yao, Zhenqing Zhang, Robert J. Linhardt

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Heparin is a polypharmacological agent with anticoagulant activity. Periodate oxidation of the nonsulfated glucuronic acid residue results in non-anticoagulant heparin derivative (NACH) of reduced molecular weight. Similar treatment of a low molecular weight heparin, dalteparin, also removes its anticoagulant activity, affording a second heparin derivative (D-NACH). A full structural characterization of these two derivatives reveals their structural differences. SPR studies display their ability to bind to several important heparin-binding proteins, suggesting potential new therapeutic applications.

Original language	English
Pages (from-to)	1067-1073
Number of pages	7
Journal	Journal of Medicinal Chemistry
Volume	62
Issue number	2
DOIs	https://doi.org/10.1021/acs.jmedchem.8b01551
State	Published - 24 Jan 2019
Externally published	Yes

Access to Document

10.1021/acs.jmedchem.8b01551

Cite this

@article{e01110f12673435f908f79c9bb6ef543,

title = "Non-Anticoagulant Low Molecular Weight Heparins for Pharmaceutical Applications",

abstract = "Heparin is a polypharmacological agent with anticoagulant activity. Periodate oxidation of the nonsulfated glucuronic acid residue results in non-anticoagulant heparin derivative (NACH) of reduced molecular weight. Similar treatment of a low molecular weight heparin, dalteparin, also removes its anticoagulant activity, affording a second heparin derivative (D-NACH). A full structural characterization of these two derivatives reveals their structural differences. SPR studies display their ability to bind to several important heparin-binding proteins, suggesting potential new therapeutic applications.",

author = "Yilan Ouyang and Yanlei Yu and Fuming Zhang and Jianle Chen and Xiaorui Han and Ke Xia and Yiming Yao and Zhenqing Zhang and Linhardt, \{Robert J.\}",

note = "Publisher Copyright: {\textcopyright} 2019 American Chemical Society.",

year = "2019",

month = jan,

day = "24",

doi = "10.1021/acs.jmedchem.8b01551",

language = "English",

volume = "62",

pages = "1067--1073",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "2",

}

TY - JOUR

T1 - Non-Anticoagulant Low Molecular Weight Heparins for Pharmaceutical Applications

AU - Ouyang, Yilan

AU - Yu, Yanlei

AU - Zhang, Fuming

AU - Chen, Jianle

AU - Han, Xiaorui

AU - Xia, Ke

AU - Yao, Yiming

AU - Zhang, Zhenqing

AU - Linhardt, Robert J.

PY - 2019/1/24

Y1 - 2019/1/24

N2 - Heparin is a polypharmacological agent with anticoagulant activity. Periodate oxidation of the nonsulfated glucuronic acid residue results in non-anticoagulant heparin derivative (NACH) of reduced molecular weight. Similar treatment of a low molecular weight heparin, dalteparin, also removes its anticoagulant activity, affording a second heparin derivative (D-NACH). A full structural characterization of these two derivatives reveals their structural differences. SPR studies display their ability to bind to several important heparin-binding proteins, suggesting potential new therapeutic applications.

AB - Heparin is a polypharmacological agent with anticoagulant activity. Periodate oxidation of the nonsulfated glucuronic acid residue results in non-anticoagulant heparin derivative (NACH) of reduced molecular weight. Similar treatment of a low molecular weight heparin, dalteparin, also removes its anticoagulant activity, affording a second heparin derivative (D-NACH). A full structural characterization of these two derivatives reveals their structural differences. SPR studies display their ability to bind to several important heparin-binding proteins, suggesting potential new therapeutic applications.

UR - https://www.scopus.com/pages/publications/85060227257

U2 - 10.1021/acs.jmedchem.8b01551

DO - 10.1021/acs.jmedchem.8b01551

M3 - Article

C2 - 30608147

AN - SCOPUS:85060227257

SN - 0022-2623

VL - 62

SP - 1067

EP - 1073

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 2

ER -

Non-Anticoagulant Low Molecular Weight Heparins for Pharmaceutical Applications

Abstract

Access to Document

Fingerprint

Cite this